back to the overview


Press Release; Berlin, June 8, 2006


EMEA grants MOLOGEN AG medicine status for their cell-based gene therapy


MOLOGEN AG (ISIN DE0006637200) announces that they obtained medicine status for their cell-based gene therapy against kidney cancer. This status was granted by Innovation Task Force (ITF), a committee of the European medicines evaluation agency, EMEA.

Others than their proprietary DNA molecules MIDGE and dSLIM, cells are not a priori regarded as medicine, and therefore this notification is of utmost importance. It is a major step forward for further clinical development of this cancer therapy in Europe.

MOLOGEN employs for this type of cancer therapy human cells derived from their proprietary master cell banks. Such cells are severalfold gene modified with MIDGE vectors and immunomodulated by dSLIM.



MOLOGEN uses its proprietary DNA technologies to create and develop treatments for high-unmet-need illnesses. The main focuses are the unique and patented MIDGE and dSLIM technologies. Based on these platforms, MOLOGEN is developing DNA-based vaccines and therapeutics to prevent or cure a wide range of diseases.

Going public in 1998, MOLOGEN was one of the first German biotechnology companies to be floated on the stock exchange. The MOLOGEN shares are traded on the Geregelter Markt in Frankfurt.


Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.


 back to the overview


Investor & Public Relations

  Joerg Petrass

Research & Development

  Dr. Matthias Schroff

Business Development

  Arlett Killat


To subscribe to our Newsletter please

 click here


To view our Reports

  click here